The construction and characterization of layered double hydroxides as delivery vehicles for podophyllotoxins.
The aim of this study was to construct PPT-LDH nanohybrids and compare their tumor inhibition effects with that of free PPT. Anticancer drug podophyllotoxin (PPT) was encapsulated in the galleries of Mg-Al layered double hydroxides (LDHs) by a two-step approach. Tyrosine (Tyr) was first incorporated into the interlayer space by co-precipitation with LDH, prop-opening the layers of Mg-Al/LDH and creating an interlayer environment inviting drug molecules. PPT was subsequently intercalated into the resulting material lamella by an ion exchange process. The intermediate and final products, which can be termed drug-inorganic nanocomposites, have been characterized by powder X-ray diffraction (XRD), UV-VIS spectrophotometer, transmission electron microscopy (TEM) and in cell culture. Our results demonstrate that the interlayer spacing distance of the PPT-LDH nanohybrids (34% w/w of drug/material) is 18.2 A. LDHs do not harm normal cells (293T) based on toxicity tests. Ex-vivo anticancer experiments reveal that the PPT-LDH nanohybrids have higher tumor suppression effects than intercalated PPT. We conclude that the higher tumor inhibition effects of PPT-LDH hybrids result from the inorganic drug delivery vehicle, LDHs.
Xue
Yan Hua
YH
School of Life Science and Technology, Tongji University, Shanghai 200092, China.
Zhang
Rui
R
Sun
Xiao Yu
XY
Wang
Shi Long
SL
D000970:Antineoplastic Agents / Q000008:administration & dosage; D049109:Cell Proliferation / Q000187:drug effects; D002478:Cells, Cultured; D003692:Delayed-Action Preparations / Q000008:administration & dosage / Q000493:pharmacokinetics; D006801:Humans; D006878:Hydroxides / Q000737:chemistry*; D049329:Nanostructures / Q000737:chemistry; D014677:Pharmaceutical Vehicles / Q000138:chemical synthesis* / Q000737:chemistry; D011034:Podophyllotoxin / Q000008:administration & dosage* / Q000493:pharmacokinetics; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D003692:Delayed-Action Preparations; D006878:Hydroxides; D014677:Pharmaceutical Vehicles; D011034:Podophyllotoxin
Biomaterials. 2004 Jul;25(15):3059-64
14967539
Pharm Res. 1989 May;6(5):408-12
2748532
J Pharm Sci. 2005 May;94(5):1135-48
15793807
Hum Gene Ther. 1995 Sep;6(9):1129-44
8527471
Biochimie. 1998 Mar;80(3):207-22
9615861
Angew Chem Int Ed Engl. 2000 Nov 17;39(22):4041-4045
11093198
Pharm Res. 1993 Jul;10(7):998-1004
8378263
J Clin Oncol. 1985 May;3(5):666-71
2582097
Pharmazie. 1988 Apr;43(4):249-51
3413211
J Natl Cancer Inst. 1988 Dec 7;80(19):1526-33
2848132
Cancer. 1991 Jan 1;67(1 Suppl):319-29
1984835
Int J Pharm. 2004 Jan 28;269(2):469-78
14706258
Int J Pharm. 2001 Jun 4;220(1-2):23-32
11376964
Trends Biotechnol. 1997 Jun;15(6):217-24
9183864
J Control Release. 2004 Mar 24;95(3):501-14
15023461